Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Parmax Pharma's Revenue for the
three
months ended in Jun. 2026 was ₹82.2 Mil. Parmax Pharma's average Accounts Receivable for the
three
months ended in Jun. 2026 was ₹31.6 Mil.
Hence, Parmax Pharma's Receivables Turnover for the
three
months ended in Jun. 2026 was 2.60.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Parmax Pharma Receivables Turnover Related Terms
Parmax Pharma Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Parmax Pharma's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:540359 vs ZTS: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Parmax Pharma's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Parmax Pharma Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Parmax Pharma's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Parmax Pharma's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Parmax Pharma (BOM:540359) has a Receivables Turnover of 2.60 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Parmax Pharma and its competitors. According to the industry distribution chart, Parmax Pharma ranks #90 out of 947 companies in the Drug Manufacturers industry, placing it in the top 9.5%.
Is Parmax Pharma's Receivables Turnover too high?
Parmax Pharma's current Receivables Turnover is 2.60. The Drug Manufacturers industry median Receivables Turnover is 5.08. Parmax Pharma's value of 2.60 is 48.8% below this industry median. Based on the distribution chart, Parmax Pharma ranks #90 out of 947 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Parmax Pharma has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Parmax Pharma's Receivables Turnover compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Parmax Pharma ranks #90 out of 947 companies for Receivables Turnover. This places Parmax Pharma in the top 10% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.08. Parmax Pharma's value of 2.60 is 48.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.08, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Parmax Pharma's current Receivables Turnover of 2.60 is 48.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Parmax Pharma and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Parmax Pharma's current Receivables Turnover is 2.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parmax Pharma stock overvalued right now?
Based on GuruFocus' analysis, Parmax Pharma (BOM:540359) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹40.79, compared to a current price of ₹132.45 — trading 224.7% above its estimated fair value. The current Receivables Turnover is 2.60 and 48.8% below the Drug Manufacturers industry median of 5.08. Parmax Pharma's overall GF Score™ is 42/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Parmax Pharma (BOM:540359), the current Receivables Turnover is 2.60 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Parmax Pharma (BOM:540359) Overvalued in 2026?
Based on GuruFocus' analysis, Parmax Pharma stock appears to be overvalued.
The current stock price of ₹132.45 is trading 224.7% above its estimated GF Value™ of ₹40.79.
GuruFocus considers Parmax Pharma to be Significantly Overvalued.
Key valuation signals for BOM:540359:
Receivables Turnover: 2.60
GF Value™: ₹40.79 vs. price of ₹132.45 (224.7% above fair value)
Industry Position: 48.8% below the Drug Manufacturers median (#90 of 947)
No single metric tells the full story. See the BOM:540359 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540359 has been successfully added to your 
